Loading company…
MetaNovas develops anti-aging and metabolic drug candidates using computational biology platforms.
Founded in 2021 and based in Shanghai, MetaNovas develops anti-aging and metabolic drugs and research programs targeting neurodegenerative diseases. It has platforms for knowledge graphs, multi-omics analysis, and clinical and literature data mining, and is developing several peptide products. In March 2026, the company closed Series A+ funding from Fuhua Capital, Hillhouse Investment, and Kangaroo Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in